WO2008019061A3 - Anti-il-6 monoclonal antibodies and uses thereof - Google Patents
Anti-il-6 monoclonal antibodies and uses thereof Download PDFInfo
- Publication number
- WO2008019061A3 WO2008019061A3 PCT/US2007/017337 US2007017337W WO2008019061A3 WO 2008019061 A3 WO2008019061 A3 WO 2008019061A3 US 2007017337 W US2007017337 W US 2007017337W WO 2008019061 A3 WO2008019061 A3 WO 2008019061A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- monoclonal antibodies
- amino acid
- well
- region selected
- acid variants
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Abstract
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2657763A CA2657763C (en) | 2006-08-03 | 2007-08-03 | Anti-il-6 monoclonal antibodies and uses thereof |
AU2007282023A AU2007282023B2 (en) | 2006-08-03 | 2007-08-03 | Anti-IL-6 monoclonal antibodies and uses thereof |
KR20097003512A KR101479537B1 (en) | 2006-08-03 | 2007-08-03 | Anti-il-6 monoclonal antibodies and uses thereof |
BRPI0715115-2A BRPI0715115A2 (en) | 2006-08-03 | 2007-08-03 | isolated monoclonal antibody, isolated nucleic acid molecule, expression vector, host cell, methods for treating a disease, and for producing an isolated monoclonal antibody, use of isolated monoclonal antibody, and, pharmaceutical composition |
EA200900037A EA200900037A1 (en) | 2006-08-03 | 2007-08-03 | MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN-6 (IL-6) AND THEIR APPLICATION |
CN2007800289537A CN101563365B (en) | 2006-08-03 | 2007-08-03 | Anti-IL-6 monoclonal antibodies and uses thereof |
JP2009522880A JP2009545319A (en) | 2006-08-03 | 2007-08-03 | Anti-IL-6 monoclonal antibody and use thereof |
EP07811042.6A EP2064241B1 (en) | 2006-08-03 | 2007-08-03 | Anti-il-6 monoclonal antibodies and uses thereof |
MX2009001110A MX2009001110A (en) | 2006-08-03 | 2007-08-03 | Anti-il-6 monoclonal antibodies and uses thereof. |
NO20090224A NO20090224L (en) | 2006-08-03 | 2009-01-15 | Anti-IL-6 Monoclonal Antibodies and Uses thereof |
IL196550A IL196550A0 (en) | 2006-08-03 | 2009-01-15 | Anti-il-6 monoclonal antibodies and uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83510706P | 2006-08-03 | 2006-08-03 | |
US60/835,107 | 2006-08-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008019061A2 WO2008019061A2 (en) | 2008-02-14 |
WO2008019061A3 true WO2008019061A3 (en) | 2008-10-09 |
Family
ID=39033490
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/017337 WO2008019061A2 (en) | 2006-08-03 | 2007-08-03 | Anti-il-6 monoclonal antibodies and uses thereof |
Country Status (17)
Country | Link |
---|---|
US (1) | US7919095B2 (en) |
EP (1) | EP2064241B1 (en) |
JP (1) | JP2009545319A (en) |
KR (1) | KR101479537B1 (en) |
CN (1) | CN101563365B (en) |
AU (1) | AU2007282023B2 (en) |
BR (1) | BRPI0715115A2 (en) |
CA (1) | CA2657763C (en) |
CO (1) | CO6150192A2 (en) |
CR (1) | CR10563A (en) |
EA (1) | EA200900037A1 (en) |
IL (1) | IL196550A0 (en) |
MA (1) | MA30653B1 (en) |
MX (1) | MX2009001110A (en) |
NO (1) | NO20090224L (en) |
WO (1) | WO2008019061A2 (en) |
ZA (1) | ZA200900514B (en) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200831528A (en) | 2006-11-30 | 2008-08-01 | Astrazeneca Ab | Compounds |
US8404235B2 (en) | 2007-05-21 | 2013-03-26 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
US7906117B2 (en) | 2007-05-21 | 2011-03-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
US9701747B2 (en) | 2007-05-21 | 2017-07-11 | Alderbio Holdings Llc | Method of improving patient survivability and quality of life by anti-IL-6 antibody administration |
US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
US20090238825A1 (en) * | 2007-05-21 | 2009-09-24 | Kovacevich Brian R | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
JP5833823B2 (en) | 2007-05-21 | 2015-12-16 | アルダーバイオ・ホールディングズ・エルエルシー | Antibodies against IL-6 and uses thereof |
US8252286B2 (en) | 2007-05-21 | 2012-08-28 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
US8178101B2 (en) | 2007-05-21 | 2012-05-15 | Alderbio Holdings Inc. | Use of anti-IL-6 antibodies having specific binding properties to treat cachexia |
EP2297202B1 (en) | 2008-05-13 | 2016-01-13 | NovImmune SA | Anti-il-6/il-6r antibodies and methods of use thereof |
US8188235B2 (en) | 2008-06-18 | 2012-05-29 | Pfizer Inc. | Antibodies to IL-6 and their uses |
JP2012503490A (en) * | 2008-09-26 | 2012-02-09 | ワイス・エルエルシー | Single chain antibody library design |
BRPI0921665A2 (en) * | 2008-11-13 | 2019-04-16 | Femta Pharmaceuticals, Inc. | Humanized anti-il-6 antibodies |
US8323649B2 (en) | 2008-11-25 | 2012-12-04 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
US8420089B2 (en) | 2008-11-25 | 2013-04-16 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
EP2361095B1 (en) * | 2008-11-25 | 2017-12-20 | AlderBio Holdings LLC | Antagonists of il-6 to raise albumin and/or lower crp |
US9452227B2 (en) | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
US9212223B2 (en) | 2008-11-25 | 2015-12-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
US8992920B2 (en) | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
US8337847B2 (en) | 2008-11-25 | 2012-12-25 | Alderbio Holdings Llc | Methods of treating anemia using anti-IL-6 antibodies |
WO2011066371A2 (en) | 2009-11-24 | 2011-06-03 | Alder Biopharmaceuticals, Inc. | Antibodies to il-6 and use thereof |
WO2011032119A1 (en) | 2009-09-14 | 2011-03-17 | The Regents Of The University Of Colorado | Modulation of yeast-based immunotherapy products and responses |
US9775921B2 (en) | 2009-11-24 | 2017-10-03 | Alderbio Holdings Llc | Subcutaneously administrable composition containing anti-IL-6 antibody |
SG183542A1 (en) | 2010-03-12 | 2012-10-30 | Immunogen Inc | Cd37-binding molecules and immunoconjugates thereof |
CA2818813C (en) | 2010-11-23 | 2020-10-06 | Alder Biopharmaceuticals, Inc. | Anti-il-6 antibodies for the treatment of oral mucositis |
US20120189621A1 (en) | 2011-01-21 | 2012-07-26 | Yann Dean | Combination Therapies and Methods Using Anti-CD3 Modulating Agents and Anti-IL-6 Antagonists |
BR112013025208A2 (en) | 2011-04-01 | 2018-09-11 | Immunogen Inc | cd-37 binding molecules and immunoconjugates thereof |
WO2013175276A1 (en) * | 2012-05-23 | 2013-11-28 | Argen-X B.V | Il-6 binding molecules |
CN103772503B (en) * | 2012-10-22 | 2017-05-10 | 泉盛生物科技股份有限公司 | Antibodies to interleukin-6 and uses thereof |
CN104903349B (en) * | 2012-11-08 | 2018-10-19 | 十一生物治疗股份有限公司 | IL-6 antagonists and its application |
US20170000900A1 (en) | 2015-06-08 | 2017-01-05 | Immunogen, Inc. | Anti-cd37 immunoconjugate and anti-cd20 antibody combinations |
EP3329018B1 (en) | 2015-07-31 | 2021-03-31 | Medimmune Limited | Il-6 antagonists for use in treating hepcidin-mediated disorders |
BR112018003147A2 (en) | 2015-08-28 | 2018-09-18 | Debiopharm International S.A. | cd37 antibodies and testing |
EP3411068A4 (en) * | 2016-02-02 | 2020-01-29 | Kadmon Corporation, LLC | Bispecific binding proteins for pd-l1 and kdr |
EP3452106A4 (en) * | 2016-05-05 | 2020-01-08 | The Trustees of The University of Pennsylvania | Dna monoclonal antibodies targeting il-6 and cd126 |
EP3535297B1 (en) | 2016-11-02 | 2022-08-10 | Debiopharm International, S.A. | Methods for improving anti-cd37 immunoconjugate therapy |
AU2018214554C1 (en) | 2017-02-01 | 2022-12-15 | Novo Nordisk A/S | Treatment of diuretic resistance |
EP3735421A4 (en) | 2018-01-05 | 2021-09-22 | Corvidia Therapeutics, Inc. | Methods for treating il-6 mediated inflammation without immunosuppression |
CN109517064B (en) * | 2018-10-10 | 2020-05-08 | 北京汇智和源生物技术有限公司 | Humanized monoclonal antibody of interleukin-6, coding gene and application thereof |
JP2022537555A (en) | 2019-06-20 | 2022-08-26 | 武田薬品工業株式会社 | Virus-based gene therapy treatment methods |
CN112279913B (en) * | 2020-10-30 | 2022-05-03 | 上海百英生物科技有限公司 | Anti-human IL-6 monoclonal antibody and application |
JP2023551542A (en) | 2020-11-30 | 2023-12-08 | エニグマ バイオインテリジェンス,インコーポレイテッド | Non-invasive assessment of Alzheimer's disease |
CN113980129B (en) * | 2021-01-15 | 2023-07-28 | 东大生物技术(苏州)有限公司 | Group of IL-11 monoclonal antibodies and medical application thereof |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0312996A2 (en) * | 1987-10-19 | 1989-04-26 | Kishimoto, Tadamitsu, Prof. | Anti-human bcdf monoclonal antibody |
EP0399429A1 (en) * | 1989-05-22 | 1990-11-28 | Toray Industries, Inc. | Anti-human interleukin-6 monoclonal antibody |
EP0410813A1 (en) * | 1989-07-28 | 1991-01-30 | Fujirebio Inc. | Anti-human BCDF monoclonal antibody and immunoassay using the same |
DE3939706C1 (en) * | 1989-12-01 | 1991-03-21 | Centre Regional De Transfusion Sanguine, Besancon, Fr | |
US5856135A (en) * | 1993-05-31 | 1999-01-05 | Chugai Seiyaku Kabushiki Kaisha | Reshaped human antibody to human interleukin-6 |
WO2004039826A1 (en) * | 2001-11-14 | 2004-05-13 | Centocor, Inc. | Anti-il-6 antibodies, compositions, methods and uses |
EP1536012A1 (en) * | 2002-08-30 | 2005-06-01 | Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute | Human antihuman interleukin-6 antibody and fragment of the antibody |
US20050196755A1 (en) * | 2000-11-17 | 2005-09-08 | Maurice Zauderer | In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL88375A (en) | 1988-11-14 | 1995-07-31 | Yeda Res & Dev | Monoclonal antibodies specifically binding to natural and recombinant interferon-beta2 and method of purification of said interferon-beta2 |
EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
JPH03139292A (en) * | 1989-05-22 | 1991-06-13 | Toray Ind Inc | Monoclonal antibody against human interleukin 6 |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
MX9204374A (en) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | RECOMBINANT ANTIBODY AND METHOD FOR ITS PRODUCTION. |
JP3614183B2 (en) * | 1993-05-31 | 2005-01-26 | 中外製薬株式会社 | Reconstituted human antibody against human interleukin-6 |
US5888510A (en) | 1993-07-21 | 1999-03-30 | Chugai Seiyaku Kabushiki Kaisha | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
US6083501A (en) | 1994-06-07 | 2000-07-04 | Toray Industries, Inc. | Drug for prevention and therapy of diseases caused by fibrinoid formation or thrombus formation in the lung and model animals of the diseases |
AU700819B2 (en) | 1994-10-07 | 1999-01-14 | Chugai Seiyaku Kabushiki Kaisha | Rheumatoid arthritis remedy containing IL-6 antagonist as effective component |
DE69525971T3 (en) | 1994-12-29 | 2013-01-10 | Chugai Seiyaku K.K. | USE OF A PM-1 ANTIBODY OR AN MH 166 ANTIBODY FOR REINFORCING THE ANTI-TUMOR EFFECT OF CISPLATINE OR CARBOPLATIN |
GB9702944D0 (en) | 1997-02-13 | 1997-04-02 | Univ Manchester | Reducing fibrosis |
DK2011514T3 (en) | 1997-03-21 | 2012-03-26 | Chugai Pharmaceutical Co Ltd | Preventive or therapeutic agent for sensitized T cell mediated diseases comprising IL-6 antagonist as an active ingredient |
PT1074268E (en) | 1998-03-17 | 2008-02-28 | Chugai Pharmaceutical Co Ltd | Preventives or remedies for inflammatory intestinal diseases containing il-6 receptor antagonist antibodies |
US7494652B1 (en) | 1998-06-10 | 2009-02-24 | Promega Corporation | Treatment of sepsis |
EP1108435B1 (en) | 1998-08-24 | 2007-01-03 | Chugai Seiyaku Kabushiki Kaisha | Preventives or remedies for pancreatitis containing anti-il-6 receptor antibodies as the active ingredient |
US7083950B2 (en) | 1998-09-25 | 2006-08-01 | Regeneron Pharmaceuticals, Inc. | High affinity fusion proteins and therapeutic and diagnostic methods for use |
AU2736400A (en) | 1999-01-27 | 2000-08-18 | University Of South Florida | Inhibition of stat3 signal transduction for human cancer therapy |
US6846486B1 (en) | 2000-02-24 | 2005-01-25 | Advanced Biotherapy Concepts, Inc. | Method of treating allergy by administering an anti-histamine antibody |
CA2407292A1 (en) | 2000-05-03 | 2001-11-08 | Medimmune, Inc. | Combination therapy of respiratory diseases using antibodies and anti-inflammatory agents |
JP4776145B2 (en) | 2000-10-25 | 2011-09-21 | 中外製薬株式会社 | Prophylactic or therapeutic agent for psoriasis containing an IL-6 antagonist as an active ingredient |
JP4889187B2 (en) | 2000-10-27 | 2012-03-07 | 中外製薬株式会社 | A blood MMP-3 concentration reducing agent comprising an IL-6 antagonist as an active ingredient |
CA2429544C (en) * | 2000-11-17 | 2010-10-19 | University Of Rochester | In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells |
WO2002070007A1 (en) | 2001-03-02 | 2002-09-12 | Medimmune, Inc. | Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists |
AU2002250236A1 (en) | 2001-03-02 | 2002-09-19 | Medimmune, Inc. | Cd2 antagonists for treatment of autoimmune or inflammatory disease |
UA80091C2 (en) | 2001-04-02 | 2007-08-27 | Chugai Pharmaceutical Co Ltd | Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist |
EP1456237A2 (en) | 2001-12-21 | 2004-09-15 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Method for cloning of variable domain sequences |
US20060275294A1 (en) | 2002-08-22 | 2006-12-07 | Omoigui Osemwota S | Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer |
EP1572103A4 (en) | 2002-11-15 | 2008-02-13 | Centocor Inc | Anti-angiogenic uses of il-6 antagonists |
CA2514997A1 (en) | 2003-02-04 | 2004-08-26 | Mohit Trikha | Use of il-6 antagonists in combination with steroids to enhance apoptosis |
EP1444989A1 (en) | 2003-02-07 | 2004-08-11 | Giorgio Dr. Stassi | Sensitizing cells for apoptosis by selectively blocking cytokines |
CN100340294C (en) | 2003-02-24 | 2007-10-03 | 中外制药株式会社 | Remedy for spinal injury containing interleukin-6 antagonist |
GB2401040A (en) | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
WO2005023193A2 (en) | 2003-09-04 | 2005-03-17 | Interleukin Genetics, Inc. | Methods of treating endometriosis |
US20050095246A1 (en) | 2003-10-24 | 2005-05-05 | Medtronic, Inc. | Techniques to treat neurological disorders by attenuating the production of pro-inflammatory mediators |
US20050100550A1 (en) | 2003-11-10 | 2005-05-12 | Mohit Trikha | Anti-angiogenic uses of IL-6 antagonists |
DE602005020743D1 (en) | 2004-02-11 | 2010-06-02 | Warner Lambert Co | PROCESS FOR TREATING OSTEOARTHRITIS WITH ANTI-IL-6 ANTIBODIES |
US20060177436A1 (en) | 2004-12-16 | 2006-08-10 | Genentech, Inc. | Methods for Treating Autoimmune Disorders |
WO2006105665A1 (en) | 2005-04-06 | 2006-10-12 | Bioartificial Gel Technologies Inc. | Hydrogel composition for modulation of topical inflammatory response |
EP1712241A1 (en) | 2005-04-15 | 2006-10-18 | Centre National De La Recherche Scientifique (Cnrs) | Composition for treating cancer adapted for intra-tumoral administration and uses thereof |
PE20061324A1 (en) | 2005-04-29 | 2007-01-15 | Centocor Inc | ANTI-IL-6 ANTIBODIES, COMPOSITIONS, METHODS AND USES |
EP2377884A1 (en) | 2005-05-10 | 2011-10-19 | Neoloch Aps | Neuritogenic peptides |
-
2007
- 2007-08-03 CN CN2007800289537A patent/CN101563365B/en not_active Expired - Fee Related
- 2007-08-03 WO PCT/US2007/017337 patent/WO2008019061A2/en active Application Filing
- 2007-08-03 CA CA2657763A patent/CA2657763C/en not_active Expired - Fee Related
- 2007-08-03 JP JP2009522880A patent/JP2009545319A/en active Pending
- 2007-08-03 EA EA200900037A patent/EA200900037A1/en unknown
- 2007-08-03 EP EP07811042.6A patent/EP2064241B1/en active Active
- 2007-08-03 MX MX2009001110A patent/MX2009001110A/en not_active Application Discontinuation
- 2007-08-03 AU AU2007282023A patent/AU2007282023B2/en not_active Ceased
- 2007-08-03 KR KR20097003512A patent/KR101479537B1/en not_active IP Right Cessation
- 2007-08-03 US US11/882,751 patent/US7919095B2/en not_active Expired - Fee Related
- 2007-08-03 BR BRPI0715115-2A patent/BRPI0715115A2/en not_active Application Discontinuation
-
2009
- 2009-01-15 NO NO20090224A patent/NO20090224L/en not_active Application Discontinuation
- 2009-01-15 IL IL196550A patent/IL196550A0/en unknown
- 2009-01-15 CR CR10563A patent/CR10563A/en unknown
- 2009-01-22 ZA ZA200900514A patent/ZA200900514B/en unknown
- 2009-01-28 CO CO09007783A patent/CO6150192A2/en unknown
- 2009-02-17 MA MA31649A patent/MA30653B1/en unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0312996A2 (en) * | 1987-10-19 | 1989-04-26 | Kishimoto, Tadamitsu, Prof. | Anti-human bcdf monoclonal antibody |
EP0399429A1 (en) * | 1989-05-22 | 1990-11-28 | Toray Industries, Inc. | Anti-human interleukin-6 monoclonal antibody |
EP0410813A1 (en) * | 1989-07-28 | 1991-01-30 | Fujirebio Inc. | Anti-human BCDF monoclonal antibody and immunoassay using the same |
DE3939706C1 (en) * | 1989-12-01 | 1991-03-21 | Centre Regional De Transfusion Sanguine, Besancon, Fr | |
US5856135A (en) * | 1993-05-31 | 1999-01-05 | Chugai Seiyaku Kabushiki Kaisha | Reshaped human antibody to human interleukin-6 |
US20050196755A1 (en) * | 2000-11-17 | 2005-09-08 | Maurice Zauderer | In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells |
WO2004039826A1 (en) * | 2001-11-14 | 2004-05-13 | Centocor, Inc. | Anti-il-6 antibodies, compositions, methods and uses |
EP1536012A1 (en) * | 2002-08-30 | 2005-06-01 | Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute | Human antihuman interleukin-6 antibody and fragment of the antibody |
Non-Patent Citations (2)
Title |
---|
SHIMAMURA T ET AL: "ANALYSIS OF INTERLEUKIN 6 (IL-6)/IL-6 RECEPTOR SYSTEM USING MONOCLONAL ANTI-IL-6 ANTIBODIES", MOLECULAR IMMUNOLOGY, ELMSFORD, NY, US, vol. 28, no. 11, 1 November 1991 (1991-11-01), pages 1155 - 1161, XP000764448, ISSN: 0161-5890 * |
WIJDENES J ET AL: "Human recombinant dimeric il-6 binds to its receptor as detected by anti-il-6 monoclonal antibodies", MOLECULAR IMMUNOLOGY, ELMSFORD, NY, US, vol. 28, no. 11, 1 January 1991 (1991-01-01), pages 1183 - 1192, XP002974189, ISSN: 0161-5890 * |
Also Published As
Publication number | Publication date |
---|---|
CO6150192A2 (en) | 2010-04-20 |
KR20090039801A (en) | 2009-04-22 |
CA2657763C (en) | 2016-05-31 |
MX2009001110A (en) | 2009-05-11 |
MA30653B1 (en) | 2009-08-03 |
IL196550A0 (en) | 2011-08-01 |
US7919095B2 (en) | 2011-04-05 |
EP2064241B1 (en) | 2015-10-07 |
CA2657763A1 (en) | 2008-02-14 |
CN101563365B (en) | 2012-10-31 |
AU2007282023B2 (en) | 2012-09-13 |
CR10563A (en) | 2009-04-14 |
NO20090224L (en) | 2009-03-31 |
US20080075726A1 (en) | 2008-03-27 |
EP2064241A2 (en) | 2009-06-03 |
BRPI0715115A2 (en) | 2013-06-04 |
JP2009545319A (en) | 2009-12-24 |
CN101563365A (en) | 2009-10-21 |
KR101479537B1 (en) | 2015-01-07 |
AU2007282023A1 (en) | 2008-02-14 |
ZA200900514B (en) | 2010-04-28 |
EA200900037A1 (en) | 2009-10-30 |
WO2008019061A2 (en) | 2008-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008019061A3 (en) | Anti-il-6 monoclonal antibodies and uses thereof | |
WO2008079246A3 (en) | Cd44 antibodies | |
WO2007024846A3 (en) | Anit-il-23 antibiodies | |
WO2006114704A3 (en) | P-cadherin antibodies | |
PH12015500248A1 (en) | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses | |
WO2006096489A3 (en) | Anti-m-csf antibody compositions having reduced levels of endotoxin | |
WO2007137984A3 (en) | Modified humanised anti-interleukin-18 antibodies | |
WO2008070344A3 (en) | Compositions and methods for binding sphingosine-1-phosphate | |
TW200722518A (en) | Sc(fv)2 structural isomers | |
WO2007113172A3 (en) | Antibodies against amyloid-beta peptide | |
NZ595235A (en) | Compositions and methods for increasing muscle growth | |
WO2010021697A3 (en) | Antibodies to ccr2 | |
WO2010017103A3 (en) | Fully human anti-human nkg2d monoclonal antibodies | |
WO2007058823A3 (en) | Anti-egfr antibodies | |
UA95478C2 (en) | Humanized c-kit antibody | |
GEP20104887B (en) | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors | |
WO2007143168A3 (en) | High affinity antibodies to human il-6 receptor | |
WO2009048537A3 (en) | Humanized antibody | |
WO2007068750A3 (en) | Immunoglobulins directed against nogo | |
NZ594682A (en) | Fully human antibodies specific to cadm1 | |
WO2007003421A3 (en) | Humanised antibodies specific for nogo-a and pharmaceutical uses thereof | |
WO2007007159A3 (en) | Anti-madcam antibodies to treat uterine disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780028953.7 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2657763 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009522880 Country of ref document: JP Ref document number: CR2009-010563 Country of ref document: CR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007282023 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200900037 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 574282 Country of ref document: NZ Ref document number: 272/KOLNP/2009 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009010128 Country of ref document: EG Ref document number: 09007783 Country of ref document: CO Ref document number: MX/A/2009/001110 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12009500227 Country of ref document: PH |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2007282023 Country of ref document: AU Date of ref document: 20070803 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020097003512 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: DZP2009000114 Country of ref document: DZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007811042 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07811042 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: PI0715115 Country of ref document: BR Kind code of ref document: A2 Effective date: 20090129 |